European radiopharma companies are raising substantial capital with funding rounds exceeding $75 million. Notably, Nuclidium AG secured $99 million to advance copper isotope-based diagnostic and therapeutic candidates, while Actithera closed a $75.5 million series A targeting fibroblast activation protein for cancer. These investments reflect growing confidence in radiopharmaceuticals for precise oncology applications and efforts to overcome manufacturing challenges.